

Subject: Molex IP Disclosure Statement for SFF-TA-1016 Rev 1.2
Date: Friday, March 22, 2024 at 2:31:21 PM Eastern Daylight Time
From: Murisa, Egide
To: disclosure@snia.org, tcmd@snia.org, Jones, Arnold
CC: Sommers, Scott, Sheldon, Steve, Murisa, Egide

To Whom It May Concern:

Based on the SFF-TA-1016 Rev 1.2 specification, Molex believes it could have several patents that may have essential claims. The patents would be related to and/or claim priority to Chinese Patent Application Serial Nos. 202310645043.4; 202311160761.9, 202330333329.x; 202330571577.8 and any foreign counterparts and related cases. This list may be updated from time to time in the event that Molex obtains a relevant granted patent.

Molex agrees that if any of the above referenced patent applications grant (or any if Molex acquires any other relevant patents) and such a patent include one or more claims that are deemed essential, Molex will grant a license to those essential claims on reasonable and non-discriminatory terms to companies requesting such a license. Please note that Molex reserves the right to increase the cost for a licensee that refuses to take a license and forces Molex to use legal action in order to enforce Molex's rights.

Steve Sheldon
Chief Counsel, IP

Office: 630-527-4336
Mobile: 630-280-1508

CONFIDENTIALITY NOTICE: This message (including any attachments) may contain Molex confidential information, protected by law. If this message is confidential, forwarding it to individuals, other than those with a need to know, without the permission of the sender, is prohibited.

This message is also intended for a specific individual. If you are not the intended recipient, you should delete this message and are hereby notified that any disclosure, copying, or distribution of this message or taking of any action based upon it, is strictly prohibited.

English | Chinese | Japanese
www.molex.com/confidentiality.html